Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PAVmed Inc. (PAVM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed, commercial-stage medical technology company. Through these documents, investors can review how PAVmed reports its operations in the medical device, diagnostics, and digital health sectors, along with detailed financial information and corporate actions.
Current reports on Form 8-K include items such as press releases announcing quarterly financial results and business updates. For example, PAVmed has filed an 8-K to furnish a press release covering financial results for the quarter ended September 30, 2025 and a related business update. These filings give context on revenue, operating expenses, non-GAAP measures such as EBITDA and adjusted loss, and commentary on the performance of subsidiaries like Lucid Diagnostics Inc. and Veris Health Inc.
Proxy materials such as the definitive proxy statement on Schedule 14A provide insight into corporate governance and stockholder proposals. PAVmed’s definitive proxy statement for a special meeting of stockholders describes proposals to approve a reverse stock split within a specified ratio range and a reduction in authorized common stock, along with the reasons for these actions, including efforts to meet Nasdaq’s minimum bid price requirement.
On this page, users can also monitor periodic reports such as Forms 10-Q and 10-K (when available), which contain comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures. These filings are important for understanding PAVmed’s financial condition, capital structure, and its activities in medical technology development, commercialization, and digital health.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping readers quickly identify information on topics such as quarterly performance, non-GAAP reconciliations, reverse stock split mechanics, and subsidiary operations. The platform also surfaces real-time updates from EDGAR, so new PAVM filings appear promptly as they are submitted.
Timothy E. Baxter, a director of PAVmed Inc. (PAVM), received a grant of 150,000 restricted shares of common stock on 09/30/2025. After the grant, Mr. Baxter beneficially owned 215,000 shares in total. The restricted shares vest on a single date, May 20, 2028, and are subject to forfeiture if the required service period is not completed. The award was made under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and was reported on a Form 4.
Michael J. Glennon, a director of PAVmed Inc. (PAVM), was granted 150,000 restricted shares on 09/30/2025 under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a reported price of $0. After the grant his total beneficial ownership is reported as 231,667 shares. The restricted shares vest on May 20, 2028 and are subject to forfeiture if the required service period is not completed. The Form 4 was signed by power of attorney on 10/02/2025.
Sundeep Agrawal, a director of PAVmed Inc. (PAVM), reported an acquisition of 150,000 shares of common stock on 09/30/2025 via restricted stock granted under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The shares carry a single vesting date of May 20, 2028 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person’s beneficial ownership is reported as 162,195 shares. The Form 4 was signed by power of attorney on 10/02/2025.
PAVmed Inc. (PAVM) reported a Form 4 showing that Michael A. Gordon, the company's General Counsel, was granted 150,000 shares of common stock on 09/30/2025. The award is restricted stock issued under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carries a single vesting date of May 20, 2028. The shares have a reported acquisition price of $0 and are subject to forfeiture if the required service period is not completed. Following the grant, the reporting person beneficially owns 150,000 shares directly. The form is signed by the reporting person on 10/02/2025.
PAVmed Inc. (PAVM) reporting person Dennis M. McGrath, who is identified as President and CFO, received a grant of 150,000 shares of restricted common stock on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carry a single vesting date of May 20, 2028; they are subject to forfeiture if the required service period is not completed. The Form 4 shows 200,834 shares beneficially owned by the reporting person after the transaction. The reported transaction lists a price of $0, indicating these were restricted shares rather than a cash purchase. The filing was executed by power of attorney and dated 10/02/2025.
Dr. Lishan Aklog, Chairman and CEO of PAVmed Inc. (PAVM), reported on Form 4 the grant of 150,000 restricted shares on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a $0 purchase price and vest on May 20, 2028, subject to forfeiture if service requirements are not met. After the transaction Dr. Aklog directly beneficially owns 228,418 shares and indirectly holds additional positions: 154 shares via his daughter, 152 via his son, 297,105 through Pavilion Venture Partners LLC (of which he is sole manager), and 1,333 through HCFP/AG LLC (co-managed). The filing was signed by power of attorney on 10/02/2025.
Shaun O'Neil, Chief Operating Officer of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025 under the company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The restricted shares carry a $0 purchase price and vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed. After the grant, the reporting person beneficially owned 167,933 shares. The filing was reported on Form 4 and signed by power of attorney on 10/02/2025.